NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Series GSE243752 Query DataSets for GSE243752
Status Public on Nov 22, 2023
Title Empagliflozin alleviates atherosclerotic calcification by inhibiting osteogenic differentiation of vascular smooth muscle cells
Organism Rattus norvegicus
Experiment type Expression profiling by high throughput sequencing
Summary SGLT-2 inhibitors, such as empagliflozin, have been shown to reduce the occurrence of cardiovascular events and delay the progression of atherosclerosis. However, its role in atherosclerotic calcification remains unclear. In this research, ApoE-/- mice were fed with western diet and empagliflozin was added to the drinking water for 24 weeks. Empagliflozin treatment significantly alleviated arterial calcification assessed by alizarin red and von kossa staining in aortic roots and reduced the lipid levels, while had little effect on body weight and blood glucose levels in ApoE-/- mice. In vitro studies, empagliflozin significantly inhibits calcification of primary vascular smooth muscle cells (VSMCs) and aortic rings induced by osteogenic media (OM) or inorganic phosphorus (Pi). RNA sequencing of VSMCs cultured in OM with or without empagliflozin showed that empagliflozin negatively regulated the osteogenic differentiation of VSMCs. And further studies confirmed that empagliflozin significantly inhibited osteogenic differentiation of VSMCs via qRT-PCR. Our study demonstrates that empagliflozin alleviates atherosclerotic calcification by inhibiting osteogenic differentiation of VSMCs, which addressed a critical need for the discovery of a drug-based therapeutic approach in the treatment of atherosclerotic calcification.
 
Overall design To investigate the function of empagliflozin in the regulation of Osteogenic differentiation of primary vascular smooth muscle cells (VSMCs), we performed gene expression profiling analysis using data obtained from RNA-seq of VSMCs cultivated in osteogenic media (10mM β-GP plus 3.5mM CaCl2) treated with or without empagliflozin for 5 days.
Web link https://pubmed.ncbi.nlm.nih.gov/38094889/
 
Contributor(s) Li J, Li C, Liu Z
Citation(s) 38094889
Submission date Sep 21, 2023
Last update date Feb 25, 2024
Contact name Junping Li
E-mail(s) lijp58@mail2.sysu.edu.cn
Organization name Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Street address 107 Yanjiang West Road, Yuexiu District, Guangzhou, Guangdong Province, China
City Guangzhou
ZIP/Postal code 510120
Country China
 
Platforms (1)
GPL25947 Illumina NovaSeq 6000 (Rattus norvegicus)
Samples (6)
GSM7795328 VSMCs Pi+E-1
GSM7795329 VSMCs Pi+E-2
GSM7795330 VSMCs Pi+E-3
Relations
BioProject PRJNA1019757

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE243752_Pi+E_vs_Pi.result.all.anno.txt.gz 3.9 Mb (ftp)(http) TXT
GSE243752_Pi+E_vs_Pi.result.diff.anno.txt.gz 59.9 Kb (ftp)(http) TXT
SRA Run SelectorHelp
Raw data are available in SRA

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap